Aqualung Therapeutics Corp.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
Phase 2
Recruiting
- Conditions
- Acute Respiratory Distress Syndrome (ARDS)
- Interventions
- Drug: ALT-100 mAbDrug: ALT-100 (Placebo)
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Aqualung Therapeutics Corp.
- Target Recruit Count
- 90
- Registration Number
- NCT05938036
- Locations
- 🇺🇸
Banner University of Arizona, Tucson, Arizona, United States
First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Aqualung Therapeutics Corp.
- Target Recruit Count
- 32
- Registration Number
- NCT05426746
- Locations
- 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath